Why did Hims & Hers miss first-quarter revenue estimates and post a surprise loss?

Hims & Hers missed first-quarter revenue estimates ($608.1 million vs. $616.85 million expected) and posted a surprise loss of 40 cents per share (vs. 4 cents profit expected) due to write-downs on ingredients used to compound semaglutide, plus one-time legal and merger costs — all stemming from its strategic shift away from compounded GLP-1 drugs toward FDA-approved branded versions like Novo Nordisk’s Wegovy.

What is Hims & Hers’ path to profitability, and when does it expect to return to profits?

Hims & Hers expects to return to profitability in 2027, citing its transition to branded GLP-1 drugs, a new partnership with Novo Nordisk to offer Wegovy, and anticipated international growth; CFO Yemi Okupe stated the company’s 'North Star' remains operating cash flow — which has stayed positive — and that it aims to be 'well-positioned for profitability in 2027.'

Hims & Hers Misses Revenue Estimates as Strategy Shift Hits Sales

May 11, 2026

Hims & Hers Health missed Q1 revenue estimates and posted a loss amid a strategic pivot to branded GLP-1 drugs like Wegovy. The company anticipates returning to profitability by 2027 following a Novo Nordisk partnership amidst tightening FDA regulations on compounded alternatives.

reuters

2026-05-11

Hims & Hers Misses Revenue Estimates as Strategy Shift Hits Sales

2026-08-10

Hims & Hers Raises Annual Revenue Forecast on Strong Subscriber Growth

Hims & Hers Misses Revenue Estimates as Strategy Shift Hits Sales

FAQ